TransCelerate BioPharma Awards Accenture New Clinical Data Sharing Services Contract

Accenture ACN has been selected by TransCelerate BioPharma Inc., a non-profit organization focused on advancing innovation in R&D for the biopharmaceutical industry, to support its Placebo and Standard of Care initiative (PSoC). The PSoC initiative has been established to maximize the value of historic clinical data collected during clinical trials, and is the first cross-therapeutic, multi-sponsor clinical data sharing initiative of its kind in life sciences designed to improve trial design and safety surveillance. Accenture will help TransCelerate member companies better aggregate, share, and use clinical data collected in the placebo and standard-of-care arms of clinical trials. This agreement aims to optimize the use and sharing of clinical data by ensuring it is compliant with the standards set by the Clinical Data Interchange Standards Consortium. Insights gained from the combined data have the potential to reduce both the time spent on, and number of patients involved in clinical trials; improve the patient experience; and enable a better understanding of diseases. Ed Bowen, Senior Director, Translational and Bioinformatics at Pfizer and the lead for this initiative, said: "Having access to this data among TransCelerate member companies has the potential to be a powerful tool for clinical research. This initiative is representative of TransCelerate's overall mission: to collaborate across the global R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of medicines." "Today the industry struggles to maximize the use of historically collected clinical data to enhance prospective study design, interpret safety signals and inform patient recruitment strategies," said Kevin Julian, managing director, Accenture Accelerated R&D Services, Life Sciences. "Working with TransCelerate we aim to provide a solution that helps strengthen these capabilities quickly and efficiently for the industry." Accenture was chosen by TransCelerate in 2012 to provide program management and change management services for the development and adoption of the TransCelerate portfolio of initiatives. In March 2015 Accenture also delivered a project to achieve an automated solution that simplifies the process of sourcing comparator drugs for TransCelerate's Comparator Network initiative. "Accenture is an important collaborator with TransCelerate," said Dalvir Gill, CEO of TransCelerate BioPharma Inc. "Accenture's deep expertise in life sciences, technology, and clinical data-related services will be instrumental in delivering a data sharing solution. This new project builds on the multi-year relationship between Accenture and TransCelerate."